Canagliflozin

Canagliflozin is an active ingredient that is used in some medicines.

The active ingredient is the chemical in a medicine that makes it work. Medicines can have more than one active ingredient and be available under different brand names. Medicines include both active ingredients and inactive ingredients.

This page about canagliflozin automatically lists related information collected from other pages of our website.

The list below also includes links to brands of medicines that contain canagliflozin, including their consumer medicine information (CMI) leaflets.

Consumers: If you have any questions about medicines, you can speak to one of our pharmacists at NPS Medicines Line by calling 1300 633 424. You can ring Monday to Friday, 9 am to 5 pm, Australian Eastern Standard Time (excluding NSW public holidays). For non-medicine products, further information may also be available from the manufacturer.

Related information - canagliflozin

Audience:
       

(Medicine)
31 May 2016 SLGT2 inhibitors are used to control blood glucose levels in people with type 2 diabetes. Read more about the benefits and side effects of SGLT2 inhibitors.
(Medicine)
03 Feb 2016 Invokana Tablets is a brand of medicine. Find out about side effects, who can and who shouldn’t use Invokana Tablets by reading the latest Australian consumer medicine information. See our tips on how to use medicines wisely and safely.
For health professionals (Health professional publication)
02 Dec 2013 The new SGLT-2 inhibitors have been PBS listed as dual oral therapy in combination with either metformin or a sulfonylurea in people with type 2 diabetes not controlled by metformin and a sulfonylurea.
(Media release)
26 Nov 2013 Australian Prescriber has published a number of articles ‘online first’ to provide prescribers and other health professionals with information on a new class of diabetes drugs – sodium-glucose co-transporter (SGLT) inhibitors. The first two drugs in this class are dapagliflozin (Forxiga) and canagliflozin (Invokana) and on 1 December 2013 both medicines will be listed on the Pharmaceutical Benefits Scheme.

Medicine brands that contain canagliflozin